Literature DB >> 20159239

Achieving asthma control in patients with moderate disease.

J Mark FitzGerald1, Neal Shahidi.   

Abstract

Patients with moderate asthma are symptomatic on an ongoing basis. They are usually treated initially with low-dose inhaled corticosteroids (ICSs) supplemented with a short-acting bronchodilator as a rescue medication. Most steroid-naive patients will achieve good control with this strategy. For patients in whom adherence, inhaler technique, environmental control, and comorbidities have been addressed but who still have uncontrolled symptoms, the addition of a long-acting beta-adrenergic agonist should be considered. Some patients might require a higher dose of ICS. Leukotriene receptor antagonists might be considered as alternate initial therapy or as an add-on to maintenance therapy with an ICS. All patients should receive a structured education program emphasizing the need for ongoing maintenance treatment, even when control is achieved. Patients should also be provided with a written action plan that clearly explains which additional anti-inflammatory therapy should be taken if asthma symptoms worsen. The most effective strategy in this situation has been shown to be the quadrupling of the maintenance dose of ICS. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20159239     DOI: 10.1016/j.jaci.2009.12.978

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  4 in total

Review 1.  Advances in pediatric asthma in 2010: addressing the major issues.

Authors:  Stanley J Szefler
Journal:  J Allergy Clin Immunol       Date:  2011-01       Impact factor: 10.793

2.  Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues.

Authors:  Paolo Montuschi
Journal:  Front Pharmacol       Date:  2011-07-14       Impact factor: 5.810

Review 3.  Role of Leukotrienes and Leukotriene Modifiers in Asthma.

Authors:  Paolo Montuschi
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-02

4.  The role of asthma guidelines in achieving current control and reducing future risk.

Authors:  J Mark Fitzgerald
Journal:  Ann Thorac Med       Date:  2012-10       Impact factor: 2.219

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.